Noa Krugliak Cleveland1, Dylan Rodriquez1, Alana Wichman1, Isabella Pan1, Gil Y Melmed2, David T Rubin3. 1. University of Chicago Medicine, 5841 S. Maryland Ave., MC 4076, Chicago, IL, 60637, USA. 2. Cedars Sinai Medical Center, Los Angeles, CA, USA. 3. University of Chicago Medicine, 5841 S. Maryland Ave., MC 4076, Chicago, IL, 60637, USA. drubin@medicine.bsd.uchicago.edu.
Abstract
BACKGROUND: Current guidelines emphasize vaccination for influenza and pneumococcus for IBD patients and the avoidance of live virus vaccines for those who are on immunosuppressive (ISS) therapy. Given the recent resurgence of measles and pertussis infections, we assessed the immune status of our IBD population in order to advise about these risks. METHODS: We prospectively collected measles and pertussis titers in our IBD patients from February 1-May 1, 2015. Immune status based on standard threshold values was determined: measles antibodies ≤0.8 antibody index (AI) = negative immunity, 0.9-1.1 AI = equivocal immunity and titers ≥1.2 AI = positive immunity. For pertussis immunity, anti-pertussis antibodies ≤5 IU/mL were considered negative immunity. Univariate analysis was performed to examine predictive factors including age, disease duration, and current medical therapies. RESULTS: A total of 122 patients' titers were assessed (77 Crohn's disease, 1 indeterminate colitis, and 45 ulcerative colitis). Sixteen (13.1 %) patients lacked detectable immunity to measles, and four (3 %) had equivocal immunity. Twelve (75 %) of the measles non-immune patients were on ISS therapy versus 65 (64 %) of 102 immune patients (OR 1.7, 95 % CI 0.5-5.9, p = 0.34). Out of 96 patients, 58 (60 %) were not immune to pertussis. Disease duration ≥10 years and age ≥50 were associated with significant lower measles titers. CONCLUSIONS: A significant number of our IBD patients lack immunity to measles, and a majority of our IBD patients do not have detectable immunity to pertussis. Importantly, the majority of the measles non-immune patients are on ISS therapy and therefore unable to receive a booster.
BACKGROUND: Current guidelines emphasize vaccination for influenza and pneumococcus for IBDpatients and the avoidance of live virus vaccines for those who are on immunosuppressive (ISS) therapy. Given the recent resurgence of measles and pertussis infections, we assessed the immune status of our IBD population in order to advise about these risks. METHODS: We prospectively collected measles and pertussis titers in our IBDpatients from February 1-May 1, 2015. Immune status based on standard threshold values was determined: measles antibodies ≤0.8 antibody index (AI) = negative immunity, 0.9-1.1 AI = equivocal immunity and titers ≥1.2 AI = positive immunity. For pertussis immunity, anti-pertussis antibodies ≤5 IU/mL were considered negative immunity. Univariate analysis was performed to examine predictive factors including age, disease duration, and current medical therapies. RESULTS: A total of 122 patients' titers were assessed (77 Crohn's disease, 1 indeterminate colitis, and 45 ulcerative colitis). Sixteen (13.1 %) patients lacked detectable immunity to measles, and four (3 %) had equivocal immunity. Twelve (75 %) of the measles non-immune patients were on ISS therapy versus 65 (64 %) of 102 immune patients (OR 1.7, 95 % CI 0.5-5.9, p = 0.34). Out of 96 patients, 58 (60 %) were not immune to pertussis. Disease duration ≥10 years and age ≥50 were associated with significant lower measles titers. CONCLUSIONS: A significant number of our IBDpatients lack immunity to measles, and a majority of our IBDpatients do not have detectable immunity to pertussis. Importantly, the majority of the measles non-immune patients are on ISS therapy and therefore unable to receive a booster.
Authors: Gil Y Melmed; Nik Agarwal; Robert W Frenck; Andrew F Ippoliti; Patricio Ibanez; Konstantinos A Papadakis; Peter Simpson; Cristina Barolet-Garcia; Joel Ward; Stephan R Targan; Eric A Vasiliauskas Journal: Am J Gastroenterol Date: 2009-09-15 Impact factor: 10.864
Authors: Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis Journal: JAMA Date: 2012-07-04 Impact factor: 56.272
Authors: Seper Dezfoli; Henry A Horton; Nattapaun Thepyasuwan; Dror Berel; Stephan R Targan; Eric A Vasiliauskas; Marla Dubinsky; David Q Shih; Manreet Kaur; Dermot P B McGovern; Andrew Ippoliti; Edward J Feldman; Gil Y Melmed Journal: Inflamm Bowel Dis Date: 2015-08 Impact factor: 5.325
Authors: Bruce E Sands; Carmen Cuffari; Jeffry Katz; Subra Kugathasan; Jane Onken; Charles Vitek; Walter Orenstein Journal: Inflamm Bowel Dis Date: 2004-09 Impact factor: 5.325
Authors: Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Samiyeh Price; Wayne Langholff; Anil Londhe; William J Sandborn Journal: Am J Gastroenterol Date: 2012-08-14 Impact factor: 10.864
Authors: Freddy Caldera; Sumona Saha; Arnold Wald; Christine A Garmoe; Sue McCrone; Bryant Megna; Dana Ley; Mark Reichelderfer; Mary S Hayney Journal: Dig Dis Sci Date: 2018-03-29 Impact factor: 3.199
Authors: Freddy Caldera; Elizabeth Ann Misch; Sumona Saha; Arnold Wald; Youqi Zhang; Jeffrey Hubers; Bryant Megna; Dana Ley; Mark Reichelderfer; Mary S Hayney Journal: Dig Dis Sci Date: 2018-10-13 Impact factor: 3.199
Authors: Gaurav Syal; Mariastella Serrano; Animesh Jain; Benjamin L Cohen; Florian Rieder; Christian Stone; Bincy Abraham; David Hudesman; Lisa Malter; Robert McCabe; Stefan Holubar; Anita Afzali; Adam S Cheifetz; Jill K J Gaidos; Alan C Moss Journal: Inflamm Bowel Dis Date: 2021-10-18 Impact factor: 5.325